← Back

Zhaoke Ophthalmology Limited

2.48-31.9%1Y · HKD

Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company operating in Hong Kong, Mainland China, South Korea, and internationally. It develops treatments for dry eye disease, including Cyclosporine A ophthalmic gel and RGN-259, as well as CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization, and IC-265 in Phase II trials for allergic conjunctivitis. The company also develops NVK-002 for myopia progression in children and adolescents, BRIMOCHOL PF and Carbachol PF for presbyopia, TAB014 for wAMD, and PAN-90806 for wAMD and DME. Additionally, it develops ZK002, Bimatoprost, Levobetaxolol HCl, Travoprost, Bimatoprost Timolol, Latanoprost Timolol, Travoprost Timolol, and Latanoprost for various ophthalmic conditions. Formerly known as China Ophthalmology Focus Limited, the company was incorporated in 2017 and is headquartered in Guangzhou, People's Republic of China.

Price · split & dividend adjusted
News & notes moving 6622.HK
Biotech & Genomic Medicine▼

Qilu Pharmaceutical's atropine sulfate eye drops application accepted, intensifying competition in children's myopia drug market

Qilu Pharmaceutical's marketing application for atropine sulfate eye drops, filed under chemical drug registration category 2.2, was accepted by the Center for Drug Evaluation of the National Medical Products Administration on July 24. The indication is to slow the progression of myopia in children. Currently, only Xingqi Pharmaceutical's 0.01% atropine sulfate eye drops have been approved for marketing in this field, in March 2024, with nationwide sales reaching 603.6 million yuan in 2025, a year-on-year increase of 212%. Similar products from companies such as Hengrui Medicine's subsidiary Shengdi Pharmaceutical and Zhaoke Ophthalmology have also entered the marketing application stage, while Ocumension Therapeutics, Shapuaisi, and JMD Biomed are in late-stage clinical trials. Qilu Pharmaceutical stated that it is currently only an application, and the specific launch time is uncertain.
Shenyang Xingq… ▲Zhaoke Ophthal… ▼Ocumension The… ▼Jiangsu Hengru… ▼Zhejiang Shapu… ▼
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
300573.CS · Competition · Positive Xingqi is the only approved product in this field; Qilu's application is still uncertain, so Xingqi's first-mover advantage is reinforced.
6622.HK · Competition · Negative Zhaoke's similar product is already in marketing application stage; Qilu's entry intensifies competition for market share.
1477.HK · Competition · Negative Qilu's application adds another competitor in the children's myopia drug market, increasing competition for Ocumension's late-stage clinical product.
600276.CG · Competition · Negative Hengrui's subsidiary Shengdi has a similar product in marketing application; Qilu's application adds competitive pressure.
603168.CG · Competition · Negative Shapuaisi's late-stage clinical product faces increased competition from Qilu's application.
极目生物 · Competition · Negative Qilu Pharmaceutical's application for atropine sulfate eye drops adds competition in the children's myopia drug market, potentially impacting 极目生物's late-stage clinical trial prospects.
Read original ↗
红星资本局·70dRead more →
6622.HK▲

Zhaoke Ophthalmology Acquires Global Rights to Atropine Sulfate Eye Drops

Zhaoke Ophthalmology announced it has acquired the global rights to NVK002 atropine sulfate eye drops, a product designed to slow the progression of myopia in children. Under the agreement, Zhaoke Ophthalmology will obtain global ownership of all intellectual property, trademarks, regulatory filings, clinical data, manufacturing capabilities, and other assets related to NVK002. Previously, the company only held exclusive licenses for Greater China, South Korea, and some Southeast Asian countries. As part of the transaction, Zhaoke Ophthalmology granted the seller a perpetual, royalty-free exclusive license for development and commercialization in the United States. After the acquisition, the company will have full control over the global development, manufacturing, and commercialization of the product. Currently, only Xingqi Ophthalmology has received approval for atropine sulfate eye drops in China. Zhaoke Ophthalmology has submitted marketing applications for two strengths of NVK002 as a modified new drug and a generic drug respectively, with approval expected within the year. Several other pharmaceutical companies, including Hengrui Medicine and Ocumension Therapeutics, are also developing similar products.
Zhaoke Ophthal… ▲Ocumension The… ▼Jiangsu Hengru… ▼Shenyang Xingq… ▲
6622.HK · Technology · Positive Zhaoke acquired global rights to NVK002, gaining full control over development and commercialization.
1477.HK · Competition · Negative Zhaoke's acquisition strengthens its position in myopia treatment, increasing competition for Ocumension's similar product.
600276.CG · Competition · Negative Zhaoke's strengthened position in atropine sulfate eye drops adds competition to Hengrui's similar development.
300573.CS · Competition · Positive Xingqi is the only approved atropine sulfate eye drop in China, but Zhaoke's pending approval may increase competition; however, Xingqi's established position is a positive.
Read original ↗
红星资本局·83dRead more →
© 2026 MarketIVAsset